GlassScriptPhysician profile
Barbara A Koewler
NPI 1588695043
$2,023.75
in general payments reported to CMS, 2019-2025
27 companies · $439 in 2025
The $439 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $50.92 · 2021: $211 · 2022: $253 · 2023: $415 · 2024: $404 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $346.40 | 2023-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $312.49 | 2019-2025 | |
| Astellas Pharma US INC | $222.65 | 2019-2025 | Veozah, Myrbetriq |
| Coopersurgical, INC. | $166.03 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Mayne Pharma Commercial LLC | $157.55 | 2022-2025 | |
| Novo Nordisk INC | $119.05 | 2022-2024 | Wegovy |
| Biogen, INC. | $92.08 | 2024-2025 | Zurzuvae |
| Minerva Surgical, INC | $84.20 | 2023-2025 | |
| Daiichi Sankyo INC. | $78.03 | 2019-2022 | |
| Hologic Sales and Service, LLC | $42.32 | 2024-2025 | Fluent Fluid Management System, Novasure, Myosure Tissue Removal Device |
| Lilly USA, LLC | $38.44 | 2025 | Zepbound, Mounjaro |
| Therapeuticsmd, INC. | $37.13 | 2020-2022 | |
| Pfizer INC. | $34.50 | 2021-2022 | |
| Exact Sciences Corporation | $32.42 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Millicent US INC | $30.96 | 2025 | Intrarosa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $29.28 | 2022-2023 | Balcoltra |
| Shield Therapeutics INC | $26.01 | 2024 | |
| Duchesnay USA Incorporated | $25.75 | 2019 | |
| Agile Therapeutics, INC. | $21.85 | 2022 | |
| Medtronic, INC. | $21.46 | 2021 | |
| Axonics, INC. | $20.66 | 2023 | Axonics |
| Pacira Pharmaceuticals Incorporated | $19.82 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.55 | 2020 | |
| Exeltis, USA INC. | $14.07 | 2023 | Slynd |
| Amag Pharmaceuticals, INC. | $12.32 | 2020 | |
| Lupin INC. | $12.11 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Koewler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.